The American Medical Association journal JAMA published a view review on 2024-2-29, titled GLP-1 Agonists for Obesity—A New Recipe for Success? (GLP-1 Agonists for Obesity Treatment - a New Secret to Success?). The author is Dariush Mozaffaria...
The American Medical Association journal JAMA published a view review on 2024-2-29, titled GLP-1 Agonists for Obesity—A New Recipe for Success? (GLP-1 Agonists for Obesity Treatment - a New Secret to Success?). The author is Dariush Mozaffarian, a cardiologist/professor at Tufts University in the United States.
Currently there are two GLP-1 Agonists (GLP-1 Agents) on the market: Danish pharmaceutical manufacturers Noor and Noodle Wegovy and Mounjaro from the US pharmaceutical manufacturers. Since Wegovy and Mounjaro are both subcutaneous injections that look like steel pens, they are commonly known as fattening pens or thin pens in Taiwan.
Both of these fattening drugs have earned huge profits for the company, so there are dozens of other brands of thin penis or oral fattening drugs that are about to be launched.
I have published two articles about Wegovy: New fattening medicines for 2021 and Magical Weight Loss Medicine in 2023, which are self-destructive.
JAMA's new article points out that although thin pens are strongly praised, they actually cannot achieve long-term weight loss, and because the price is expensive, it is ultimately just a waste of health insurance resources. The author believes that to achieve truly effective long-term weight loss, diet and exercise must be achieved.
I now organize and translate the points of this article as follows:
From 2021 to 2023, the shares of Noor and Node and Rong have more than tripled, and the combined market value is currently exceeding $1 trillion. However, there are clinical and public confusion about the expenses, tolerances and acquisitions of the real world.
Slim pens are sold in the United States at $12,000 to $16,000 per year; even with the largest dealer discount, the annual spending may exceed $6,500. If all eligible U.S. adults receive thin penis treatment at a discount, the annual expenses will reach $600 billion, equivalent to the sum of all other U.S. drug spending.
In the experiment to establish the effect of thin pen, the weight was reduced to the plateau period within 12 to 18 months. Moreover, if the medication is stopped, the patient will usually recover the reduced weight within one year. For the payer, this creates a high cost situation. Weight decreases early, but then becomes stable and requires years of continuous treatment to maintain the initial effect. This explains why these drugs are not cost-effective even with health benefits and discounted prices, with incremental costs per quality adjustment life year ranging from $237,000 to $483,000.
The long-term tolerance in the real world is also very low. In a large analysis, only 27% of thin pen users remained on the use after 1 year. Since the reduced weight usually recovers after the medication is stopped, this brings another troublesome problem to the payer: If most patients eventually stop using thin penis and their weight is reversed, the initial investment may be inappropriate.
When faced with this dilemma, another solution can be considered: treatment of thin and thin penis in stages, plus long-term lifestyle planning. Such plans should include nutrition, cooking, sports and sleep, and leverage distance medicine, applications, peer support, artificial intelligence and gaming. In this proposed example, all eligible patients will receive leep penis treatment and lifestyle planning, and then discontinue leep penis from 12 to 18 months, but maintain their lifestyle planning for a long time.
It is now time to test this program, which may begin to curb the health and cost burdens brought by obesity.
Original text: Slim pen, is it valid?Responsible editor: Gu Zihuan
